Promin

History

The first synthesis of Promin is sometimes credited to Edward Tillitson and Benjamin F. Tullar of Parke, Davis, & Co. pharmaceuticals in August 1937. However, although Parke-Davis did in fact synthesize the compound, it seems certain that they were not the first; in cooperation with J. Wittmann, Emil Fromm synthesised various sulfone compounds in 1908, including both dapsone and some of its derivatives, such as promin. Fromm and Wittmann however were engaged on chemical rather than medical work, and no-one investigated the medical value of such compounds until some decades afterwards.

Initially, Promin appeared to be safer than dapsone, so it was further investigated at the Mayo Clinic as a treatment for tuberculosis in a guinea pig model. Because it was already known that leprosy and tuberculosis were both caused by mycobacteria (Mycobacterium leprae and Mycobacterium tuberculosis, respectively), Guy Henry Faget of the National Leprosarium in Carville, Louisiana, requested information about the drug from Parke-Davis. They, in turn, informed him of the work being done on leprosy in rats by Edmund Cowdry at the Washington University School of Medicine. His successful results, published in 1941, convinced Faget to begin human studies, both with promin and sulfoxone sodium, a related compound from Abbott Laboratories. The initial trials were on six volunteers, and were then expanded and replicated in different locations. Despite severe side effects that caused the initial tests to be suspended temporarily, the drug was shown to be effective. This breakthrough was reported worldwide, and led to a reduction in the stigma attached to leprosy, and consequent better treatment of patients, at the time still referred to as "inmates", and forbidden from using public transport.

Pharmacology

Promin is heat-stable and water-soluble, and can therefore be heat-sterilized. It can be injected intravenously,

Beyond its solubility, however, promin was later found to have no real advantages over the simpler compound dapsone (which is administered in tablet form). Promin and other sulfones can also not be used as substitutes for dapsone when intolerance develops, as this is a general reaction to sulfones, and not specific to dapsone.

Today, the drugs of choice for treating leprosy are dapsone, rifampicin and clofazimine.

References

References

1. (2009). "War and disease: biomedical research on malaria in the twentieth century". Rutgers University Press.
2. (2011). "Public Health: The Development of a Discipline". Rutgers University Press.
3. (November 1943). "The Promin Treatment of Leprosy". Public Health Reports.
4. (1966). "Reprint: The promin treatment of leprosy. A progress report". International Journal of Leprosy and Other Mycobacterial Diseases.
5. (June 1979). "Dapsone". Clinical and Experimental Dermatology.
6. "Current Data on Promin Therapy; reprinted in The Star October-December 2003".
7. (1989). "The story of sulfones in tropical medicine and dermatology". International Journal of Dermatology.
8. (January 2003). "Multi-drug Regimen in Leprosy and its impact on Prevalence of the Disease". Medical Journal, Armed Forces India.
9. Sneader, Walter. (2005). "Drug discovery: a history". Wiley.
10. Tayman, John. (2006). "The Colony". Simon and Schuster.
11. (30 December 1946). "Hope for Lepers". Time Magazine.
12. (2002). "Synthetic Drugs". Mittal Publications.
13. (2004). "Clinical Leprosy". Jaypee Brothers Medical Publishers (P) Ltd.
14. (2008). "Textbook Of Pharmacology". Elsevier India Pvt. Ltd..
15. (2011). "The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs". John Wiley & Sons.